Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
03 04 2023
Historique:
received: 14 08 2022
accepted: 28 03 2023
medline: 5 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: epublish

Résumé

There is an ongoing debate on the COVID-19 infection fatality rate (IFR) and the impact of COVID-19 on overall population mortality. Here, we addressed these issues in a community in Germany with a major superspreader event analyzing deaths over time and auditing death certificates in the community.18 deaths that occurred within the first six months of the pandemic had a positive test for SARS-CoV-2. Six out of 18 deaths had non-COVID-19 related causes of death (COD). Individuals with COVID-19 COD typically died of respiratory failure (75%) and tended to have fewer reported comorbidities (p = 0.029). Duration between first confirmed infection and death was negatively associated with COVID-19 being COD (p = 0.04). Repeated seroprevalence essays in a cross-sectional epidemiological study showed modest increases in seroprevalence over time, and substantial seroreversion (30%). IFR estimates accordingly varied depending on COVID-19 death attribution. Careful ascertainment of COVID-19 deaths is important in understanding the impact of the pandemic.

Identifiants

pubmed: 37012282
doi: 10.1038/s41598-023-32441-7
pii: 10.1038/s41598-023-32441-7
pmc: PMC10069345
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5440

Informations de copyright

© 2023. The Author(s).

Références

Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
Euro Surveill. 2020 May;25(19):
pubmed: 32431289
Lancet Infect Dis. 2021 Apr;21(4):e75-e76
pubmed: 32763195
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Intern Med. 2022 Sep;292(3):409-427
pubmed: 35411985
Eur J Clin Invest. 2021 May;51(5):e13554
pubmed: 33768536
Trop Med Infect Dis. 2022 Mar 05;7(3):
pubmed: 35324591
Epidemiology. 2021 Jul 1;32(4):518-524
pubmed: 33935138
BMJ. 2021 Feb 24;372:n415
pubmed: 33627311
Lancet Reg Health Eur. 2021 Jul;6:100109
pubmed: 33997835
Eur Rev Med Pharmacol Sci. 2021 May;25(9):3610-3613
pubmed: 34002836
JAMA Intern Med. 2020 Oct 1;180(10):1336-1344
pubmed: 32609310
Nature. 2023 Jan;613(7942):130-137
pubmed: 36517599
Int J Environ Res Public Health. 2020 Oct 17;17(20):
pubmed: 33080869
J Infect. 2021 May;82(5):186-230
pubmed: 33271171
Lancet Reg Health Am. 2022 Sep;13:100303
pubmed: 35782204
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1762-1766
pubmed: 33237893
J Urban Health. 2022 Oct;99(5):922-935
pubmed: 35688966
Eur J Epidemiol. 2021 Jun;36(6):581-588
pubmed: 34322831
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Clin Microbiol. 2021 Oct 19;59(11):e0113821
pubmed: 34379530
J Glob Health. 2020 Dec;10(2):020503
pubmed: 33110586
J Infect. 2020 Nov;81(5):797-801
pubmed: 32956730
PLoS One. 2020 May 12;15(5):e0233074
pubmed: 32396542
High Alt Med Biol. 2021 Dec;22(4):406-416
pubmed: 34905395
Euro Surveill. 2020 Jul;25(26):
pubmed: 32643601
EBioMedicine. 2021 Mar;65:103259
pubmed: 33662833
Environ Res. 2020 Sep;188:109890
pubmed: 32846654
PLoS One. 2022 Nov 2;17(11):e0275967
pubmed: 36322565
PLoS Comput Biol. 2021 Sep 20;17(9):e1009436
pubmed: 34543264
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Thorax. 2022 Nov;77(11):1113-1120
pubmed: 34819384
J Public Health (Oxf). 2023 Mar 14;45(1):e7-e9
pubmed: 34977938
Tumori. 2021 Oct;107(5):446-451
pubmed: 33176598
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
Sci Rep. 2021 Feb 19;11(1):4263
pubmed: 33608563
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330709
Hist Philos Life Sci. 2021 Jan 8;43(1):4
pubmed: 33420572
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
BMC Infect Dis. 2021 Aug 30;21(1):889
pubmed: 34461847
J Infect. 2021 May;82(5):162-169
pubmed: 33766553

Auteurs

Enrico Richter (E)

Institute of Virology, University Hospital, University of Bonn, Bonn, Germany.
German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.

Dominik Liebl (D)

Institute of Finance and Statistics and Hausdorff Center for Mathematics, University of Bonn, Bonn, Germany.

Bianca Schulte (B)

Institute of Virology, University Hospital, University of Bonn, Bonn, Germany.
German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.

Nils Lehmann (N)

Institute of Medical Informatics, Biometry und Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.

Christine Fuhrmann (C)

Clinical Study Core Unit, Study Center Bonn (SZB), Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.

Karl-Heinz Jöckel (KH)

Institute of Medical Informatics, Biometry und Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.

John P A Ioannidis (JPA)

Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, USA.

Hendrik Streeck (H)

Institute of Virology, University Hospital, University of Bonn, Bonn, Germany. Hendrik.Streeck@ukbonn.de.
German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany. Hendrik.Streeck@ukbonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH